Jennifer Cain Email & Phone Number

Foster City, CA, US

• Led a team of 14 people to initiate and advance projects targeting key cancer immune evasion and oncogenic signaling mechanisms. Through increasing scope and responsibility, influenced Oncology strategy and played.
• Pioneered and implemented a strategy to target tumor intrinsic drivers of immune evasion from target identification through IND-enabling efforts, delivering multiple projects to the Gilead Oncology internal and.
• Led cross-functional teams within Gilead and with external collaborators; guided direction of multiple strategic collaborations through roles as Joint Steering Committee Member, Biology lead and subject matter expert.
• Evaluated and prospectively identified Corporate Development opportunities, leading to accomplishments including but not limited to extension of the Nurix degrader collaboration as well as initiation of Genesis AI and.
• Impacted Gilead Research objectives and culture through active participation in the Oncology Leadership Team, Seattle site Senior Leadership Team, and multiple initiatives including revising the Biology Career.
• Mentored and developed technicians and scientific staff through balance of direct guidance and coaching, proactive identification of growth opportunities and recognition of achievements.

Foster City, CA, US

Foster City, CA, US

Redwood City, CA, US

• Led a team of 3 people generate key data to drive lead identification, MOA evaluation, biomarker identification and safety risk mitigation, advancing eight biologics into clinical development.
• Designed and implemented experimental plans that employed in vivo pharmacology, flow cytometric analysis, in vitro evaluation and genetic analysis to enable data-driven decisions on novel therapeutics targeting.
• Identified and performed preclinical validation of potential predictive biomarkers and patient stratification approaches, some of which were incorporated into clinical trial design and/or resulted in patents.
• Spearheaded safety risk mitigation preclinical studies that resulted in clinical trial design changes for WNT targeting agents vantictumab and ipafricept to include bisphosphonate treatment as a method to counter.
• Discovered therapeutic potential of WNT and RSPO targeting antibodies in fibrotic diseases, resulting in an opportunity for drug repositioning as well as two single author patents and publication of a manuscript with.
• Authored regulatory documents including IND application primary reports, pharmacology and nonclinical summary overviews, and nonclinical portion of an Investigator’s Brochure for anti-RSPO3 antibody 131R10.

Redwood City, CA, US

Redwood City, CA, US

South San Francisco, California, US

Molecular Oncology